Ibio, Inc. (IBIO) — 10-K Filings
All 10-K filings from Ibio, Inc.. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
iBio Raises $46.5M, Advances Obesity Pipeline with AI-Driven Antibodies
— Sep 5, 2025 Risk: high
iBio, Inc. (IBIO) is a preclinical stage biotechnology company focused on developing precision antibodies for cardiometabolic and obesity treatments, leveraging -
iBio, Inc. Files 2024 10-K Report
— Sep 20, 2024 Risk: medium
iBio, Inc. filed its 2024 10-K report for the fiscal year ending June 30, 2024. The company, formerly known as iBioPharma, Inc., is involved in the pharmaceutic
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX